Med Tech Talks Podcast

In this episode of Med Tech Talks, Bionics Institute CEO Robert Klupacs is joined by Jan Janssen , Chief Technology Officer of Cochlear Ltd , the global leader in implantable hearing solutions. Jan has spent more than three decades at the forefront of medical technology innovation, helping shape the development of the world's most advanced cochlear implant systems. As Cochlear's Chief Technology Officer, he leads the company's global research and development strategy, overseeing multidisciplinary teams that are pushing the boundaries of hearing technology, digital health, and implantable medical devices. Throughout his career, Jan has played a pivotal role in translating breakthrough engineering and scientific research into technologies that have transformed the lives of hundreds of thousands of people living with hearing loss. His work spans implant design, sound processing, connectivity, and the next generation of smart hearing solutions, ensuring Cochlear remains at the forefront of innovation in hearing healthcare. What makes Jan's story particularly compelling is his commitment to building on the extraordinary legacy established by Professor Graeme Clark, a shared founder of Cochlear and the Bionics Institute. Under his technical leadership, Cochlear continues to advance that legacy—bringing together engineering, clinical science, and digital technologies to improve hearing outcomes for people around the world. Today's conversation is an opportunity to explore not only where cochlear implant technology has come from, but where it's heading next—from artificial intelligence and personalised hearing solutions to the future of connected healthcare and global innovation. Updated version 05/08/22

Calling in from the United States, Guy is widely regarded as the pioneer of modern evangelism in the technology industry, having played a pivotal role in building a passionate developer and user community around the Macintosh during its formative years. At a time when personal computing was still in its infancy, Guy helped translate complex technology into something accessible, inspiring, and deeply human. Since his time at Apple, Guy has become a globally respected voice on innovation, entrepreneurship, and the art of storytelling – something we are passionate about at the Bionics Institute. As an author, speaker, and venture capitalist, he has worked with countless startups and leaders, helping them to refine their vision, communicate their ideas, and bring transformative products to market. He also has a very successful podcast, Guy Kawasaki’s Remarkable People Podcast, which I recommend all our listeners should view after this podcast. Guy's latest book is called Everybody Has Something to Hide, and it will help you strengthen your privacy and security. What sets Guy apart is his unique ability to bridge technology and impact—championing not just great products, but the ideas and values that make a difference in people’s lives. Updated version 05/08/22

Navi Medical is an Australian medtech company with a very clear and compelling mission: to improve outcomes for some of the most vulnerable patients in our healthcare system—critically ill newborns and children. The company was founded on a simple but striking reality: many of the devices used in neonatal and paediatric care today are not designed for children at all, but adapted from adult medicine. In response, Navi has focused its efforts on developing purpose-built technologies for paediatric care, working closely with clinicians in neonatal and paediatric intensive care units to understand real-world challenges and design solutions that genuinely improve safety and outcomes. Navi’s latest development is the Neonav device – an ECG tip-location system that improves umbilical monitoring for the most fragile neonatal patients. It achieved FDA registration in 2025. As CEO, Alex has led Navi from its early beginnings in Melbourne through to clinical development and commercialisation, building a multidisciplinary team spanning engineering, clinical care and business, all united by a shared goal: delivering brighter, healthier futures for children. Updated version 05/08/22

In this latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Andrew Nash, former CSO of CSL. CSL is an Australian success story and one of the world’s leading biotechnology companies. CSL has a remarkable history spanning over a century, and a global reputation for developing and delivering life-saving medicines, particularly in immunology, haematology, and vaccines. As Chief Scientific Officer, Andrew led CSL’s global research and early development strategy, playing a pivotal role in advancing innovative therapies from discovery through to clinical development, and ultimately to patients around the world. Today, Andrew is a Director of: The Garvan Institute of Medical Research, the Burnet Institute, ASX listed Arovella, Jumar Incubator, Brandon Capital’s BioCatalyst and also part of the Bionics Institute’s own Industry Advisory Committee. In this episode, you will learn from Andrew about: Andrew's journey from academia to CSO of CSL His thoughts on the opportunity for innovation in Australia What Andrew would recommend to aspiring med tech and bio tech enterpreneurs to be successful Learn more about Dr Andrew Nash Learn more about CSL Updated version 05/08/22

In this latest episode of Med Tech Talks, Robert Klupacs is joined by Brendon Gardner, CEO of The Royal Victorian Eye and Ear Hospital (Eye and Ear) in Melbourne. The Royal Victorian Eye and Ear Hospital is Australia’s only specialist eye, ear, nose and throat hospital and has been operating since 1863. The Eye and Ear sees over 250,000 patients a year and offers over 110 different outpatient clinics for the diagnosis, monitoring and treatment of vision and hearing loss. The hospital also has a 24-hour emergency department for patients requiring urgent care and treatment. Brendon Gardner first joined the Victorian Public Health care system in 1990 as a Health Information Manager and over the following 35 years, has held a variety of roles including 9 years as Chief Operating Officer of Peninsula Health. In 2019, he was appointed as CEO of the Eye and Ear. In this episode, you will learn from Brendon about: Brendon’s journey to becoming CEO of a major hospital in Australia The mission and legacy of the Eye and Ear Brendon’s objectives for the future of the Eye and Ear. Learn more about Brendon Gardner and the executive team at the Eye and Ear Hospital. Learn more about the Royal Victorian Eye and Ear Hospital. Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Alastair Hick, Chief Commercialisation Officer at Monash University. With a PhD in Chemical Ecology and an MBA from the Judge Business School at the University of Cambridge, Alastair has a wealth of experience both in Australian and overseas markets and brings an ecosystem approach to commercialisation and innovation. At Monash University, Alastair has been responsible has developed a successful IP commercialisation program and an also oversees The Generator, a hub that develops the entrepreneurial talent of Monash’s students, staff, and alumni. Alastair has recently established a $15 million Monash/Breakthrough Victoria Pre-Seed fund and is chair of its investment committee. He was also a founding director of the $30 million Trans-Tasman Commercialisation Fund; is a director of Monash University spinouts Jupiter Ionics, Phrenix Therapeutics, Myostellar and Flex Immunotherapeutics; as well as an early-stage investor Uniseed and therapeutics development company BioCurate. In this episode, you will learn from Alastair about: The evolution of the commercialisation ecosystem at Monash University The role of entrepreneurial talent in innovation success Challenges in scaling and accessing investment Potential role of the government in supporting Australian innovation The importance of mentorship and confidence in entrepreneurship. Learn more about Dr Alastair Hick. Learn more about The Generator. Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Scott Kirkland, CEO and Managing Director of EMVision Medical Devices. EMVision (ASX:EMV) is an ASX listed, Australian med tech company focused on developing portable brain imaging devices using electromagnetic (EM) technology. It was spun out of University of Queensland in 2017 and had its IPO in late-2018. EMVision’s primary product is a portable scanner designed to quickly and non-invasively detect and monitor neurological conditions like stroke. Unlike traditional imaging methods such as CT or MRI, EMVision’s technology allows for bedside or on-the-go imaging, which can be particularly useful in emergency settings or in rural and remote locations to improve healthcare access. Scott has a wealth of experience in the emerging tech both here and overseas, having previously been Head of Client Sales at Quantcast, a US-based technology company. He is also a member of the Australian Institute of Company Directors. In this episode you will hear about: How EMVision is using ultra high frequency radio signals to differentiate stroke types, with the aim of speeding up diagnosis and treatment particularly within the first hour post-onset of a stroke Findings from the 300-patient trial* conducted in Australia, and the company’s plans for a pivotal US trial Learnings from EMVision’s capital raising, which led to a AUD$15M investment from Keysight Technologies The importance for startups to build strategic relationships early on and to utilise finite resources efficiently Scott’s advice for budding entrepreneurs and those seeking mentorship. Learn more about Scott Kirkland and EMVision Medical Devices. * EMVision released EMView study data subsequent to this recording, see ASX release ‘Algorithms deliver excellent results in EMView study’ 12th Nov. Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Justin Zenanko, co-founder, CEO and president of SynerFuse™, a medical device company based in the United States developing an innovative solution to reduce chronic back pain and improve patient quality of life. Justin and his team have patented the SynerFuse e-TLIF™ procedure which aims to make traditional spine implant surgery more successful and cost effective by combining neuromodulation at the time surgeons are performing fusion back surgery. SynerFuse has completed a proof-of-concept study of 15 patients and they're coming up to a 12-month review of post-surgery results in October. A certified public accountant, Justin has experience in corporate finance, entrepreneurship and startup development. He has previously led fundraising efforts resulting in $68 million of investment, including $34 million in angel funding and 34 million in Series A funding from a strategic investor. In this episode you will hear about: The global need to address opioid dependency by developing innovative drug-free treatments for chronic pain How SynerFuse’s e-TLIF technology stimulates the dorsal root ganglion as part of spinal fusion surgery – a world-first approach How Justin and his co-founders overcame skepticism from specialists and the challenges of the COVID pandemic to get FDA approval on a feasibility study Why Justin has invested his own money into SynerFuse and his advice to other unconventional entrepreneurs. Learn more about SynerFuse and the e-TLIF procedure . Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Amir Zalcenstein, Managing Director of SYNthesis BioVentures. SYNthesis BioVentures is a registered early-stage venture Capital Limited partnerships fund, focused on early-stage therapeutics investing in projects from discovery through preclinical proof of concept and IND enabling studies. Amir and the team are investing in small molecule therapeutics, biologics and cell and gene therapies for conditions with significant unmet need. Their aim, to accelerate the development of cutting-edge therapies and technologies, ultimately improving patient outcomes and delivering value to their investors. Along with a PhD in molecular biology and an MBA, Amir has an extensive background in healthcare and international operations experience, having previously been head of business development for BiondVax, CEO of Amorphical and SoluBest, and a healthcare investment manager at OneVentures. In this episode you will hear about: How SYNthesis BioVentures is supporting early-stage research, Opportunities to partner with overseas biotech firms and license underutilised, innovative therapies for western markets The challenges of financing biotech innovations, and the role of crossover funds in bridging early-stage investments with public markets The importance of smart collaboration, and the need for startups to assemble a varied and knowledgeable team. Learn more about SYNthesis BioVentures Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Anne-Laure Puaux, inaugural CEO of WEHI Ventures and Head of Business Development at WEHI. WEHI Ventures manages 66ten, a first of its kind pre-seed and seed strategic investment fund of $66 million, dedicated to ideas developed by or in collaboration with, WEHI. With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, 66ten is the largest internal pre-seed and seed fund created by an Australian medical research institute, established to bridge the gap between scientific discoveries and commercial viability. Before joining WEHI, Anne-Laure worked in Europe, US, Asia and Australia as part of biotech companies and multinational pharmaceutical companies such as GSK. Through these roles, she gained extensive global experience designing, evaluating, negotiating, and closing deals between academic research institutions, biotech companies, private investors and large multinational companies. She has also completed a PhD in Immunology and an MBA. In this episode you will hear about: How WEHI Ventures is focusing on turning early-stage discoveries into commercial successes, and its strategic management approach to high-risk, high reward projects that may be too risky or too early-stage for traditional investors The importance of collaboration between academia and industry in translating early-stage discoveries into market-ready therapies Anne-Laure’s insights into how Australia needs to strengthen its innovation ecosystem to catalyse biotech commercialisation The strategic importance of mentorship when opportunities to explore different career pathways may be limited. Learn more about WEHI Ventures Learn about Dr Anne-Laure Puaux Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Megan Baldwin, Founder, Chief Innovation Officer and Executive Director of Opthea Limited. Opthea limited is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases. They have a world class team of ophthalmology experts working to develop breakthrough therapies for those who suffer from retinal disease. Megan has over 20 years of experience focusing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications. With a PhD in medicine from the University of Melbourne, and having conducted her postdoctoral studies at Genentech, Megan joined Circadian Technologies Limited, now Opthea, in 2008 as Head of Preclinical R&D, and became Chief Executive in 2014. Today, she's a member of the Australian Institute for Company Directors, a board member of AusBiotech and serves on the boards of public and private companies. In this episode you will hear about: How Opthea is working to improve outcomes for patients with wet AMD. Insight into Opthea’s strategy for attracting investment in its early-stage research and beyond What Megan thinks Australia needs to do in order to support translation of Australian innovation Megan’s advice for seeking mentorship and the importance of looking outside of your network. Learn more about Opthea. Read about Megan Baldwin. Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Bronwyn Le Grice, CEO and Managing Director of ANDHealth. Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy. In 2017, she founded ANDHealth – which is now one of Australia’s leading health technology commercialisation organisations. It’s flagship ANDHealth+ program has a successful track record in taking businesses to scale, with companies selected in the program raising over $150 million in dilutive and non-dilutive funding, creating 400+ jobs, undertaking 72 clinical studies and impacting over 700,000 patients over the past 6 years. In this episode, you will learn more about: How digital health technology could shape the future of health care. Opportunities digital health provides to increase efficiency of care. Advice for digital health companies thinking of being part of an incubator or accelerator. Some of the key challenges faced by Australia in building a world class digital health industry. Discover more about ANDHealth. Read about Bronwyn Le Grice Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Alon Greenspan, Managing Partner at Mind Ventures. Mind Ventures is touted as the world’s first mental health-focused for-profit venture fund. Seeded by the Black Dog Institute, Mind Ventures invests in scalable, evidence-based solutions across the mental health spectrum, from illness to well-being. Alon has a wealth of international global tech M&A and venture capital experience, having previously worked at Jelix Ventures, Herzog Fox, and Arnold Bloch Liebler. With degrees in commerce and law, he is also an active angel investor and start-up advisor. In this episode you will hear about: The mission of Mind Ventures and the need for innovations in mental health The role of an angel investor and the benefits for founders in connecting with them Alon’s advice for start ups and building long term relationships as an entrepreneur Lessons Alon has learned as an impact investor. Learn more about Mind Ventures Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Stephen Tomisich, Co-founder and CEO of Trajan Scientific and Medical. Based in Melbourne, Trajan develops and manufactures analytical science instruments, devices and solutions for health care, as well as for food and environment analysis – the only company of its kind listed on the ASX. Stephen has a strong acquisition strategy, having grown Trajan from a kitchen table concept in 2011 to a global collaborator. Over the last 13 years, Trajan has acquired twelve businesses across the US, Europe and Asia; developing Trajan’s key capabilities and product lines for emerging technologies. In this episode, you will hear more about: Trajan’s unique business model and approach to acquisitions How purpose, passion and an ‘all in’ mindset laid the foundations for global success Why it’s important to be your own threat as an innovator Four books Stephen recommends entrepreneurs read. Learn more about Trajan Scientific and Medical. Stephen is a panellist at the upcoming Bionics Institute Innovation Lecture on 29 May in Melbourne. Learn more about the event and register your interest in attending . Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Chris Smith, a partner at Brandon Capital - Australasia's leading life science venture capital firm. Chris has extensive experience in the global biotech industry. With a PhD in immunology and an MBA specialising in innovation and entrepreneurship from the University of Cambridge; he has also previously been a business development manager with CSL; and is currently a Director of Aravax, Denteric, Ena Respiratory, MycRx, Q-Sera and Axelia Oncology, just to name a few. In this episode, you will hear more about: Tips for pitching to investors and building a relationship with venture capital firms Demystifying the role of a VC in research and development Brandon Capital’s incubator approach to risk and investing in early-stage innovations. Learn about Dr Chris Smith Visit the Brandon Capital website Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Steve Wesselingh, CEO of the National Health and Medical Research Council (NHMRC). An infectious disease physician and researcher in HIV vaccine development and the impact of the microbiome on human health, Steve has a wealth of medical experience, clinical leadership, and national and international success. The NHMRC is Australia's lead agency, driving innovative health and medical research to improve the health of all Australians. Along with providing an ethical framework for health and medical research in our country, the NHMRC supports the discovery of new knowledge and its translation into public health, health services and medical products to improve health outcomes for all Australians. In this episode you will hear about: Steve’s journey to becoming one of the world’s leading HIV researchers. The influence international experience in the US and Papua New Guinea had on his career Funding opportunities that could help Australia improve med tech or clinical outcomes Steve’s priorities as CEO of the NHMRC over the next 24 months and beyond, including government strategy input, and working more closely with the Australian Centre for Disease Control (CDC) Learn more about Professor Steve Wesselingh Read more about the NHMRC . Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Dean Freestone, Co-Founder of Seer Medical. A modern Australian innovation success story, Seer Medical was founded in 2017 and specialises in the early detection and diagnosis of epilepsy. The company has developed a highly innovative, portable video-EEG-ECG recording system that patients can take home with them, rather than being limited to hospital use. Dr Freestone was one of three co-founders of Seer and was CEO until 2023. Today, he holds a board position at Seer Medical. In this episode you will hear about: Dean’s unique journey from his school days all the way to being Co-Founder at Seer Medical. How Seer Medical provides revolutionary new care and patient monitoring practices for patients with epilepsy. The sacrifices and challenges Dean faced on the commericalisation journey to make Seer Medical a success. Learn more: Learn more about Dr Dean Freestone. Find out more about Seer Medical. Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by the Honourable Jaala Pulford, Chair of MTPConnect, Vice Chancellor’s Fellow at the University of Melbourne, and former Minister of the Parliament of Victoria. Jaala is well known for her career in public service where she has held several significant portfolios, including Minister for Agriculture, Minister for Small Business and Minister for Innovation, Medical Research and the Digital Economy. In her role as Minister for Innovation, Medical Research and the Digital Economy, Jaala was at the forefront of agendas to boost Victoria’s innovation ecosystem including the $2 billion Breakthrough Victoria Fund and the securing of both Moderna and BioNTech vaccines for Melbourne. In this episode you will hear about: Jaala’s career as a politician and her journey from Castlemaine, Victoria to the being a Minister in the Victorian Parliament. Insights into her time as Minister for Innovation, Medical Research and the Digital Economy which coincided with the COVID-19 pandemic. Her mission as Chair of MTPConnect and her thoughts on how Australia can improve its innovation ecosystem. Learn more: Learn more about Jaala Pulford. Find out more about MTPConnect. Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Associate Professor Fiona Brownfoot, specialist obstetrician at the Mercy Hospital for Women, clinician scientist at the University of Melbourne and Co-Founder of Kali Healthcare. Kali Healthcare is undergoing an exciting commericalisation journey and aims to transform pregnancy monitoring through the development of a wearable device that will allow expecting mothers to monitor foetal heartbeats at home. In her role as Associate Professor of Obstetrics at the University of Melbourne, she heads the Obstetric Diagnostics and Therapeutics Group – a multidisciplinary team of scientists and engineers focused on developing new treatments for obstetric conditions – whilst mentoring PhD students to become the next generation of clinician scientists. In this episode you will hear about: How Kali Heathcare aims to improve foetal monitoring with new portable, wearable technology in order to detect and prevent pregnancy complications The commericalisation journey of Kali Healthcare Fiona’s thoughts on the power of mentorship to propel the next generation of clinician scientists. More information: Learn more about Associate Professor Fiona Brownfoot. Read more about Kali Healthcare. Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Devinder Chauhan, a highly respected retinal ophthalmologist and Founding CEO of Macuject. Macuject is a digital health company that harnesses AI to provide imaging and data solutions for ophthalmologists to them make clinical decisions when treating age-related macular degeneration. Dr Chauhan founded Macuject in 2017 and is currently making the transition from clinician to entrepreneur as he and his team aim to roll this product out in eye clinics both domestically and internationally to improve visual outcomes for patients worldwide. In this episode you will hear about: Devinder’s career as a retinal ophthalmologist and why he founded Macuject How Macuject aims to transform the treatment of age-related macular degeneration The lessons Devinder has learned as he moved from the clinic to become an entrepreneur. More information: Learn more about Dr Devinder Chauhan. Read more about Macuject. Updated version 05/08/22